Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: DE-090; KB 2796; Lomerizine hydrochloride; Migsis

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Organon; Pfizer
  • Developer Merck & Co; MSD KK; Pfizer; Santen Pharmaceutical
  • Class Antimigraines; Eye disorder therapies; Piperazines; Vasodilators
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II Glaucoma
  • Discontinued Cerebral infarction

Most Recent Events

  • 03 Sep 2015 Phase-II development for Glaucoma is ongoing in Japan
  • 13 May 2009 Lomerizine is still in phase II development for glaucoma in Japan
  • 04 Dec 2007 Lomerizine is still in phase II development for glaucoma in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top